english

Samsung Life Science Fund Invests $10 Million in U.S. Alzheimer’s Blood Test Company

Samsung Life Science Fund is investing $10 million in a company developing technology for Alzheimer’s disease diagnostics. Samsung C&T announced on the 13th that it will invest $10 million (approximately…

Cheon Okhyeon

2025-03-13

Celltrion Secures FDA IND for ADC Cancer Therapy…First Step in New Drug Development

Celltrion has taken its first step as a new drug developer. Celltrion announced on the 5th that it has received Investigational New Drug (IND) clearance from the U.S. Food and…

Cheon Okhyeon

2025-03-05

Celltrion’s Bone Disease Biosimilar Wins FDA Approval in the U.S.

Celltrion announced on the 4th that its bone disease treatment biosimilars Stoboclo and Osenvelt—biosimilars of Prolia and Xgeva (active ingredient denosumab)—have received approval from the U.S. Food and Drug Administration…

Cheon Okhyeon

2025-03-04

Celltrion’s Achievement: Remsima Becomes Korea’s First Global Blockbuster Drug

Celltrion's autoimmune disease treatment, Remsima (ingredient: infliximab), has surpassed annual sales of 1.2 trillion KRW, becoming Korea’s first global blockbuster drug. On the 25th, Celltrion announced its consolidated preliminary results,…

Cheon Okhyeon

2025-02-26

Competitors Surge While Handok’s 70th Anniversary Marks a Setback

“We will show a dynamic development on the 70th anniversary of our founding. 2024 will be the year of a turnaround in growth.” Kim Young-jin, the chairman and owner of…

Cheon Okhyeon

2025-02-25

Epilepsy Drug ‘Cenobamate’ Nears Korea Launch…Dong-A ST applies for approval

The domestic introduction of SK Biopharmaceuticals’ epilepsy drug ‘Cenobamate’ (marketed as ‘Xcopri’ in the U.S.) is underway. Cenobamate, first launched in the U.S., has rapidly expanded its market presence, with…

Cheon Okhyeon

2025-02-20

Livalozet Faces Fierce Generic Challenge… Will JW Pharmaceutical Stand Firm?

JW Pharmaceutical’s hyperlipidemia combination product, Livalozet which combines pitavastatin and ezetimibe and accounts for 10% of its total sales is expected to face fierce competition from generic drugs this year.…

Cheon Okhyeon

2025-02-18

SK Biopharm Strengthens R&D with Former GSK Experts at U.S. Subsidiary

SK Biopharm is strengthening its research and development capabilities by securing top-tier talent. The company announced on the 17th that its U.S.-based research-focused subsidiary, SK Life Science Labs, has recruited…

Cheon Okhyeon

2025-02-17